Holen Sie sich die Stockscreener-App
1.99
3.65%
0.07
Handel nachbörslich:
2.05
0.06
+3.02%
Schlusskurs vom Vortag:
$1.92
Offen:
$1.94
24-Stunden-Volumen:
58,819
Relative Volume:
0.78
Marktkapitalisierung:
$20.82M
Einnahmen:
$10.16M
Nettoeinkommen (Verlust:
$-47.57M
KGV:
-0.2415
EPS:
-8.24
Netto-Cashflow:
$-42.73M
1W Leistung:
-0.50%
1M Leistung:
+39.16%
6M Leistung:
-50.62%
1J Leistung:
-81.61%
1-Tages-Spanne:
$1.93
$2.01
1-Wochen-Bereich:
$1.84
$2.19
52-Wochen-Spanne:
$1.02
$11.49
Curis Inc Stock (CRIS) Company Profile
Firmenname
Curis Inc
Sektor
Branche
Telefon
617-503-6500
Adresse
128 SPRING STREET, LEXINGTON, MA
Vergleichen Sie CRIS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRIS
Curis Inc
|
1.99 | 20.92M | 10.16M | -47.57M | -42.73M | -8.24 |
|
ONC
Beigene Ltd Adr
|
238.76 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.03 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2548 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
596.85 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
72.69 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2023-11-17 | Eingeleitet | Truist | Buy |
| 2022-04-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-10-13 | Eingeleitet | Raymond James | Outperform |
| 2021-03-25 | Eingeleitet | B. Riley Securities | Buy |
| 2020-07-29 | Eingeleitet | Laidlaw | Buy |
| 2020-07-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-10-24 | Eingeleitet | Guggenheim | Buy |
| 2016-03-02 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-08-11 | Eingeleitet | FBR Capital | Outperform |
| 2015-01-22 | Bestätigt | Oppenheimer | Outperform |
| 2015-01-21 | Bestätigt | ROTH Capital | Buy |
| 2014-05-09 | Bestätigt | Oppenheimer | Outperform |
| 2013-10-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2013-09-30 | Eingeleitet | Chardan Capital Markets | Buy |
| 2012-11-14 | Eingeleitet | Stifel Nicolaus | Hold |
| 2012-01-31 | Bestätigt | Brean Murray | Buy |
| 2012-01-31 | Bestätigt | Summer Street Research | Buy |
| 2011-12-09 | Eingeleitet | Oppenheimer | Outperform |
| 2011-10-06 | Eingeleitet | Summer Street Research | Buy |
| 2011-09-22 | Eingeleitet | MLV Capital | Buy |
| 2011-03-21 | Bestätigt | Brean Murray | Buy |
| 2010-02-26 | Bestätigt | Roth Capital | Buy |
| 2010-01-07 | Eingeleitet | Roth Capital | Buy |
Alle ansehen
Curis Inc Aktie (CRIS) Neueste Nachrichten
Curis Approves Key Amendments at Annual Meeting - TipRanks
What is HC Wainwright’s Estimate for Curis Q2 Earnings? - Defense World
Curis (NASDAQ:CRIS) Receives Buy Rating from HC Wainwright - Defense World
Curis (CRIS) Sees Positive Rating Action from HC Wainwright & Co - GuruFocus
Curis assumed with a Buy at H.C. Wainwright - TipRanks
H.C. Wainwright sets $17 target for Curis stock with Buy rating - Investing.com Nigeria
Curis (CRIS) Gains Buy Rating with Promising Cancer Therapy Deve - GuruFocus
Curis (CRIS) Gains Buy Rating with Promising Cancer Therapy Developments | CRIS Stock News - GuruFocus
Curis Provides Third Quarter 2023 Business Update - Seeking Alpha
Curis (NASDAQ:CRIS) Now Covered by Analysts at StockNews.com - Defense World
FY2025 EPS Estimates for Curis Reduced by Cantor Fitzgerald - Defense World
Curis highlights progress in lymphoma and AML trials with expanded patient enrollment - MSN
Curis, Inc. (NASDAQ:CRIS) Q1 2025 Earnings Call Transcript - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Curis (CRIS), Ardent Health Partners, Inc. (ARDT) and Agilon Health (AGL) - The Globe and Mail
Curis (NASDAQ:CRIS) Coverage Initiated at StockNews.com - Defense World
Curis (CRIS) Reports Q1 Loss, Tops Revenue Estimates - MSN
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | CRIS Stock News - GuruFocus
Curis Inc (CRIS) Q1 2025 Earnings Call Highlights: Financial Improvements and Strategic Developments - Yahoo Finance
Curis Inc (CRIS) Q1 2025 Earnings Call Highlights: Financial Imp - GuruFocus
Curis Inc (CRIS) Q1 2025 Earnings Call Highlights: Financial Improvements and Strategic Developments By GuruFocus - Investing.com Canada
Curis Inc. Reports Q1 2025 Progress and Financials - TipRanks
Curis Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Curis Inc. Earnings Call: Clinical Advances Amid Cash Concerns - TipRanks
Curis: Q1 Earnings Snapshot - MySA
Curis Q1 2025 Earnings Call Transcript - MarketBeat
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GuruFocus
Curis, Inc. (CRIS) Advances Emavusertib Studies with Positive Da - GuruFocus
Curis (CRIS) Strengthens Leadership with New Chief Medical Officer | CRIS Stock News - GuruFocus
Curis appoints Ahmed Hamdy as Chief Medical Officer - TipRanks
Curis reports Q1 EPS ($1.25), consensus ($1.26) - TipRanks
Earnings call transcript: Curis Inc. Q1 2025 sees stock surge despite losses - Investing.com India
Curis Provides First Quarter 2025 Business Update - StreetInsider
Curis (CRIS) Expands Leadership and Advances Clinical Studies | - GuruFocus
Curis Provides First Quarter 2025 Business Update | CRIS Stock N - GuruFocus
Curis Inc (CRIS) Q1 2025 Earnings: EPS of -$1.25 Misses Estimates, Revenue of $2.4M Falls Short - GuruFocus
Curis (CRIS) Expands Leadership and Advances Clinical Studies | CRIS Stock News - GuruFocus
Curis Provides First Quarter 2025 Business Update | CRIS Stock News - GuruFocus
CURIS INC SEC 10-Q Report - TradingView
Curis Inc Q1 Loss Decreases, Beats Estimates - Nasdaq
Curis Inc (CRIS) Q1 2025 Earnings Report Preview: What To Expect - GuruFocus
Curis Provides Third Quarter 2024 Business Update - Seeking Alpha
Geode Capital Management LLC Raises Position in Curis, Inc. (NASDAQ:CRIS) - Defense World
Curis FY2025 EPS Estimate Increased by Cantor Fitzgerald - Defense World
Finanzdaten der Curis Inc-Aktie (CRIS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.60%
6.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):